Letter from Oxford Haemophilia Centre to all Haemophilia Centre Directors. The letter concerns concerns 4 commercial companies introducing preparations of processed Factor VIII in an attempt to reduce the risk of transmitting hepatitis B and non-A non-B. The letter discusses the use of products on a named-patient basis rather than conducting clinical trials, the efficacy of testing on chimpanzees and also the heat treatment process.